XBiotech Inc. (XBIT)
Oxford Ledge is still expanding full research coverage of XBIT. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
XBiotech develops True Human monoclonal antibodies from natural human immune responses to treat inflammatory and infectious diseases.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 10-Q Quarterly financial report (unaudited) 2026-05-14
- 10-K/A Amended annual report 2026-04-29
- 10-K Annual financial report with audited statements 2026-03-13
- 8-K Departure/election of directors or officers 2025-12-09
- 10-Q Quarterly financial report (unaudited) 2025-11-12
Source: SEC EDGAR.
Annual results
5 years of annual figures for XBIT, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | — | -$45.5M | -$1.49 |
| 2024 | — | -$38.5M | -$1.26 |
| 2023 | $0 | -$24.6M | -$0.81 |
| 2022 | $4.0M | -$32.9M | -$1.08 |
| 2021 | $18.4M | -$17.4M | -$0.58 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for XBIT. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open XBIT in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.